KIR3DL2-BINDEMITTEL

European patent · EP2897979 · In force

Register entry

Publication number
EP2897979
Application number
EP13765702
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Sep 17, 2013
Published
Jul 29, 2015
Granted
Feb 13, 2019
Protection ends at the latest
Sep 16, 2033
Next annual fee due
Sep 30, 2027
IPC classes
C07K 16/28 (2006.01)
G01N 33/569 (2006.01)
Priority
US 201261702823 P 19.09.2012
PCT application
PCT/EP2013/069293 17.09.2013
PCT publication
WO2014/044681 27.03.2014
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Oct 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.09.2026 → 30.09.2027

    Published in Swissreg on 01.10.2026

  2. Oct 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.09.2025 → 30.09.2026

    Published in Swissreg on 01.10.2025

  3. Oct 3, 2024

    Change

    Published in Swissreg on 03.10.2024

  4. Oct 2, 2023

    Change

    Published in Swissreg on 02.10.2023

  5. Oct 6, 2022

    Change

    Published in Swissreg on 06.10.2022

  6. Feb 13, 2019

    Granted

    Published in Swissreg on 13.02.2019

Parties

Holder

Innate Pharma

117, Avenue de Luminy, 13009 Marseille, FR

Inventor

SICARD, Hélène

F-13009 Marseille, FR

GAUTHIER, Laurent

F-13008 Marseille, FR

PATUREL, Carine

F-69280 Marcy l'Etoile, FR

ROSSI, Benjamin

F-13008 Marseille, FR

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.